Chloroquine/Hydroxychloroquine and SARS-CoV 2; Lessons from Case-Control Studies

Dear Editor. In December 2019, a novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV 2) was emerged in Wuhan, Hubei Province, China [1]. We are lives in global pandemic of coronavirus disease 2019 (COVID‐19); However, we have limited therapeutic agents for treatment of COVID-19 and reduction of mortality caused by this virus; there is no FDA approved option against SARS-CoV 2 which is global concern [2]. According to review of the literatures, there are suggested several drugs including Remdesivir, Favipiravir, Ribavirin, Interferons, Lopinavir/ritonavir, Oseltamivir, Chloroquine, hydroxychloroquine, and azithromycin, Convalescent plasma, Herbal medications, nonsteroidal antiinflammatory drugs (NSAIDs), Mycophenolic acid, Monoclonal or polyclonal antibodies, and, Angiotensin‐converting enzyme 2 gene‐based peptides for combating with SARS-CoV 2 [3]; but there is no conclusive evidence for efficacy and safety of these therapeutic agents against COVID-19 [4-5].